Skip to main content
. Author manuscript; available in PMC: 2016 Jan 1.
Published in final edited form as: J Cardiovasc Pharmacol. 2015 Jan;65(1):54–61. doi: 10.1097/FJC.0000000000000163

Figure 2.

Figure 2

A & B. Temporal effects of erlotinib with or without aprepitant treatment for up to 9 weeks on rat plasma magnesium (A) and substance P (SP) (B) levels. Blood was sampled at specified times from rats treated with erlotinib (starting 10 mg/kg/day, oral) and/or aprepitant (starting 2 mg/kg/day, oral). (A) Plasma was assessed for magnesium by flame emission atomic absorption spectroscopy. Data are the means ± SEM of 5-7 animals per group. * p <0.05,** p <0.01 and # p <0.001 compared with the time-matched control group; + p<0.055 versus erlotinib alone (B) Plasma SP was assessed by a colorimetric ELISA kit. Values for erlotinib ± aprepitant rats were compared to time-matched controls (100%), and are means ± SEM of 4-6 rats per group. * p <0.05 and ** p <0.01 compared with the time-matched control group; + p <0.05 versus erlotinib alone.